Product Description
Sarolaner (PF-6450567) is an orally active and broad-spectrum ectoparasiticide. Sarolaner is an isoxazoline compound which shows efficacy against fleas and ticks on dogs, with a LC80 value of 0.3 μg/mL against C. felis and a LC100 value of 0.003 μg/mL against O. turicata[1].
[1]. McTier TL, et al. Discovery of sarolaner: A novel, orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs. Vet Parasitol. 2016 May 30;222:3-11.
AI Product Description
*The following content is generated by AI and is for reference only.
Sarolaner, chemically designated as PF-6450567, is a novel isoxazoline class antiparasitic agent developed by Zoetis for the treatment and prevention of ectoparasite infestations in companion animals. With the molecular formula C21H18ClF3N4O3 and CAS number 1295954-85-4, this compound represents a significant advancement in veterinary parasitology due to its potent neurotoxic activity against arthropods while maintaining a high safety profile for dogs and cats.
The primary mechanism of action involves the selective modulation of gamma-aminobutyric acid (GABA)-gated chloride channels and glutamate-gated chloride channels in insects and ticks. Unlike older insecticides that may affect mammalian nervous systems, Sarolaner exhibits a highly selective affinity for invertebrate receptors, effectively paralyzing and killing fleas, ticks, and other biting parasites before they can transmit diseases or cause severe dermatitis. This selectivity allows for once-monthly oral administration, providing rapid onset of action often within four hours of ingestion.
Clinically, Sarolaner is indicated for the treatment of flea infestations (Ctenocephalides felis) and tick infestations caused by Ixodes scapularis, Amblyomma americanum, Dermacentor variabilis, and Rhipicephalus sanguineus sensu lato in dogs. It is also approved for use in cats to control flea populations. Its efficacy extends beyond simple eradication; by eliminating vectors rapidly, it plays a crucial role in preventing vector-borne diseases such as Lyme disease, ehrlichiosis, and anaplasmosis. The drug is typically formulated as chewable tablets flavored to ensure high palatability, facilitating easy administration without the stress associated with topical applications.
As part of the broader isoxazoline family, which includes drugs like fluralaner and afoxolaner, Sarolaner has become a cornerstone in modern veterinary preventive care strategies. Its broad-spectrum activity against both adult parasites and developing stages makes it particularly valuable in managing heavy infestations. Furthermore, its pharmacokinetic properties allow for sustained protection throughout the month, offering pet owners a convenient and reliable solution. Ongoing research continues to validate its long-term safety and efficacy, solidifying its position as a critical tool in safeguarding animal health against the growing threat of resistant parasite strains globally.